AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00614666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nikkomycin Z
Description: Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~* 50 mg BID (n=8) vs placebo capsule BID (n=2)~* 250 mg BID (n=8) vs Placebo capsule BID (n=2)~* 500 mg BID (n=8) vs Placebo capsule BID (n=2)~* 750 mg TID (n=8) vs Placebo capsule TID (n=2)~At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.~Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization.
Study NCT04330638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study NCT04330638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra will be given as a daily subcutaneous injection of 100 mg for 28 days or until hospital discharge, whichever is first
Study NCT03512210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir (SOF/VEL)
Description: 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.
Study NCT03512210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal Monitoring (MINMON) Strategy
Description: MINMON Strategy:~1. No pre-treatment HCV genotyping~2. Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry~3. No scheduled on-treatment laboratory monitoring or clinic visits~4. Remote contact with participants at week 4 and week 22
Study NCT01266291 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vigabatrin
Description: Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
Study NCT04330638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Siltuximab
Description: Siltuximab will be given via single IV infusion at a dose of 11 mg/kg
Study NCT04330638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab will be given via single IV infusion at a dose of 8 mg/kg with a maximum infusion of 800 mg/injection
Study NCT01596582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Assessment
Description: Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid. The ACNI uses a point based system to stratify patients into low (mean rate of ACN \~3%) versus intermediate/high (\~ 8%) risk groups based on responses to 6 items: age (50-59, 60-69, 70+), sex (male/female), race/ethnicity (non-Hispanic black, other), smoking history (never, \<20 years, 20+ years), daily alcohol intake (\< 2 vs. >/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never). The index represents a prototype version of the Advanced Colorectal Neoplasia Index (Am J Gastroenterol 2015;110:1062-71).
Study NCT04879550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Antithrombin III
Description: Antithrombin III deficiency causes thrombosis. Is thrombosis in ECMO patients related to Antithrombin III deficiency? Groups with and without thrombosis will be separated and whether it is related to Antithrombin III deficiency will be evaluated.
Study NCT02211326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm for warfarin
Description: Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.
Study NCT02211326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard initiation dose for warfarin
Description: Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
Study NCT01274195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study NCT02679261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral administration atorvastatin 20 mg per day
Study NCT02679261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration placebo
Study NCT01417299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RPh201
Description: Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
Study NCT01417299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Patients will receive 400 microliter s.c., of saline twice a week for 3 months
Study NCT01978613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-0987
Description: Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.
Study NCT01978613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablets for one-daily oral administration.
Study NCT02106299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regen sling
Description: Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).
Study NCT02106299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tension-free vaginal tape-obturator(TVT-O)
Description: Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
Study NCT03327987 — intervention group
Intervention type: BIOLOGICAL
Intervention: standard of care influenza vaccine
Description: The standard of care annual 2017-2018 influenza vaccine will be used for this study.
Study NCT03887676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen
Description: Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg
Study NCT03887676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as disintegrating tabs, round, white and beveled edges
Study NCT00554970 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MAP0010 low dose
Description: a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
Study NCT00554970 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MAP0010 high dose
Description: a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
Study NCT00554970 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide inhalation suspension 0.25mg
Description: a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
Study NCT00554970 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide inhalation suspension 0.5mg
Description: a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
Study NCT00862160 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROCsafeTM
Description: using minimized perfusion circuit while CABG
Study NCT00626431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate - Formulation A
Description: Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
Study NCT00626431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate - Formulation B
Description: Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
Study NCT02566954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D measurement of the lower limb by EOS
Description: The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)
Study NCT04208841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-Centered Care Quality Improvement Collaborative Sustain
Description: Sustain improvements during QI collaborative focused on PCC
Study NCT04208841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-Centered Care Quality Improvement Collaborative Spread
Description: Implement change package developed during QI Collaborative
Study NCT00398008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Subutex
Description: Opioid agonist medication to treat opiate dependence
Study NCT00398008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Opioid antagonist medication to treat opiate dependence
Study NCT00398008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drug counseling
Description: DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
Study NCT04210206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHE-diet
Description: phenylalanine-restricted diet with phenylalanine free supplements for 8 weeks
Study NCT02373800 — intervention group
Intervention type: DEVICE
Intervention: Cervical ultrasound with elastography
Description: Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
Study NCT01881126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.01%
Description: Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
Study NCT01881126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travatan 0.004%
Description: Travatan 0.004% administered to both eyes once daily for 12 weeks.
Study NCT01881126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol 0.5%
Description: Timolol 0.5% administered to both eyes once daily for 12 weeks.
Study NCT01881126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypromellose 0.3%
Description: Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
Study NCT04598724 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Survey will be administered involving questions regarding knowledge and perception of palliative care.
Study NCT02057900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human embryonic stem cell-derived CD15+ Isl-1+ progenitors
Description: Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
Study NCT01410773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninja 2 Investigational Blood Glucose Monitoring System
Description: The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
Study NCT03541070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiology tape
Description: Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
Study NCT00765388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Uro
Description: The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
Study NCT00765388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hollister
Description: The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
Study NCT01245712 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Undergo APBI delivered with proton radiation
Study NCT01245712 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo APBI delivered with proton radiation
Study NCT01245712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00584727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric contact lens
Description: contact lens
Study NCT00584727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alphafilcon A toric
Description: contact lens
Study NCT00584727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A sphere
Description: contact lens
Study NCT00149513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Case Management
Description: A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
Study NCT00149513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care.
Study NCT01064232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone Tablets 1 mg
Study NCT01064232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone Tablets 1 mg
Study NCT02464449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: AI-CBT
Description: AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.
Study NCT02464449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Standard Telephone CBT
Description: Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
Study NCT01177904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cease progsterone at 5
Description: Cease administration of progsterone at first US at 5 weeks
Study NCT01177904 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group: progesterone 8
Description: Control group: progesterone until 8 weeks of pregnancy
Study NCT00419263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir 150 mg
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
Study NCT00419263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir 300 mg
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
Study NCT00419263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
Study NCT02567084 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CERAMENT™ |BONE VOID FILLER
Description: Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
Study NCT05045625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Study Electrode
Description: The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
Study NCT02990533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Study NCT02990533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement
Study NCT02990533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Study NCT02990533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Injection
Study NCT02990533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Study NCT02880475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXN PR tablet
Description: Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
Study NCT02990533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo supplement
Study NCT03015402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: 40 mg PO (by mouth) TID (three times each day) for 10 weeks
Study NCT03015402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 10 weeks
Study NCT00528775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: 4 mg/m2 IV
Study NCT00528775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic procedure
Description: Treatment with 150 joules from laser
Study NCT00712361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)
Description: Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
Study NCT00775710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal non-invasive ventilation
Description: Prolongation of non-invasive ventilation during 3 nights.
Study NCT02451527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
Study NCT04181528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty implant
Description: In patients undergoing unilateral TKA, decide the implant of TKA (anatomically aligned or conventional TKA implant) will be decided using ramdon number table
Study NCT04181528 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty implant
Description: In patients undergoing unilateral TKA, decide the implant of TKA (anatomically aligned or conventional TKA implant) will be decided using ramdon number table
Study NCT03773250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: The intervention has an intensive phase and a maintenance phase.
Study NCT03773250 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral intervention
Description: The intervention has an intensive phase and a maintenance phase.
Study NCT04724538 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-pertechnetate aerosol
Description: 99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
Study NCT04724538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-pertechnetate aerosol
Description: 99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
Study NCT02451527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
Study NCT03407599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster aspart
Description: An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.
Study NCT00781729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga, one hour class, 3 times per week, for 24 weeks
Description: Yoga, one hour class, 3 times per week, for 24 weeks
Study NCT03407599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart (NovoRapid®)
Description: An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.
Study NCT02955264 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-Galactose
Description: D-Galactose is an oral powdered dietary supplement to be taken by mouth.